Current Neurology and Neuroscience Reports

, Volume 10, Issue 2, pp 140–146 | Cite as

Botulinum Toxin Type A for Chronic Migraine



Chronic migraine (CM) is the leading cause of chronic daily headache, a common and debilitating headache syndrome. The management of CM patients is challenging, with only limited benefit from available oral preventive medications. Botulinum neurotoxin (BoNT) has been used extensively to treat disorders associated with increased muscle tone. More recent scientific data support an analgesic effect of the toxin. The pharmacokinetic and pharmacodynamic profiles of BoNT make it an appealing candidate for migraine prevention. Results from older clinical trials on the efficacy of the toxin in CM were inconclusive. However, recent trials using more stringent inclusion criteria have shown positive results, supporting the use of the toxin in some patients with this disorder. This review summarizes the scientific data on the analgesic properties of BoNT, as well as the clinical data on the efficacy of the toxin in treating CM.


Botulinum toxin Chronic migraine 



Dr. Ashkenazi received honoraria from MediCom Worldwide for writing commentaries on various topics in headache for its website


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl 1):9–160.Google Scholar
  2. 2.
    Bigal ME, Lipton RB, Tepper SJ, et al.: Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 2004, 63:843–847.PubMedGoogle Scholar
  3. 3.
    Dodick DW: Clinical practice. Chronic daily headache. N Engl J Med 2006, 354:158–165.CrossRefPubMedGoogle Scholar
  4. 4.
    Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81–89.CrossRefPubMedGoogle Scholar
  5. 5.
    Silberstein SD, Goadsby PJ: Migraine: preventive treatment. Cephalalgia 2002, 22:491–512.CrossRefPubMedGoogle Scholar
  6. 6.
    Ashkenazi A, Levin M, Dodick DW: Peripheral procedures: nerve blocks, peripheral neurostimulation and botulinum neurotoxin injections. In Wolff’s Headache and Other Head Pain. Edited by Silberstein SD, Lipton RB, Dodick DW. New York: Oxford University Press; 2007:767–792.Google Scholar
  7. 7.
    Turton K, Chaddock JA, Acharya KR: Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002, 27:552–558.CrossRefPubMedGoogle Scholar
  8. 8.
    Brin MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997, 6:S146–S168.CrossRefPubMedGoogle Scholar
  9. 9.
    Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669–676.CrossRefPubMedGoogle Scholar
  10. 10.
    Ashkenazi A, Silberstein SD: Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 2004, 55:505–518.CrossRefPubMedGoogle Scholar
  11. 11.
    Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245–258.CrossRefPubMedGoogle Scholar
  12. 12.
    McMahon HT, Foran P, Dolly JO, et al.: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992, 267:21338–21343.PubMedGoogle Scholar
  13. 13.
    Durham PL, Cady R, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125–133.CrossRefPubMedGoogle Scholar
  15. 15.
    Oshinsky ML: Botulinum toxins and migraine: how does it work. Practical Neurol 2004, 4:S10–S13.Google Scholar
  16. 16.
    •• Antonucci F, Rossi C, Gianfranceschi L, et al.: Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008, 28:3689–3696. This very interesting study showed a transfer of active BoNT-A through axonal transport and transcytosis to sensory synapses.Google Scholar
  17. 17.
    Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400–404.CrossRefPubMedGoogle Scholar
  18. 18.
    Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19:488–496.CrossRefPubMedGoogle Scholar
  19. 19.
    • Ranoux D, Attal N, Morain F, Bouhassira D: Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008, 64:274–283. This important, well-designed study showed an analgesic effect of BoNT-A in patients with neuropathic pain.Google Scholar
  20. 20.
    • Yuan RY, Sheu JJ, Yu JM, et al.: Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009, 72:1473–1478. This is another well-designed study that showed efficacy of BoNT-A in treating painful diabetic neuropathy.Google Scholar
  21. 21.
    Mathew NT, Frishberg BM, Gawel M, et al.: Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293–307.CrossRefPubMedGoogle Scholar
  22. 22.
    Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315–324.CrossRefPubMedGoogle Scholar
  23. 23.
    Ondo WG, Vuong KD, Derman HS: Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004, 24:60–65.CrossRefPubMedGoogle Scholar
  24. 24.
    Silberstein SD, Stark SR, Lucas SM, et al.: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126–1137.CrossRefPubMedGoogle Scholar
  25. 25.
    Freitag FG, Diamond S, Diamond M, Urban G: Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008, 48:201–209.PubMedGoogle Scholar
  26. 26.
    Aurora SK, Schim JD, Cutrer FM, et al.: Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 1 trial double-blind phase [abstract]. Cephalalgia 2009, 29:S29.CrossRefGoogle Scholar
  27. 27.
    Dodick DW, Smith TR, Becker WJ, et al.: Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase [abstract]. Cephalalgia 2009, 29:S29.CrossRefGoogle Scholar
  28. 28.
    Jakubowski M, McAllister PJ, Bajwa ZH, et al.: Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006, 125:286–295.Google Scholar
  29. 29.
    Mathew NT, Kailasam J, Meadors L: Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008, 48:194–200.PubMedGoogle Scholar
  30. 30.
    Eross EJ, Gladstone JP, Lewis S, et al.: Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005, 45:308–314.CrossRefPubMedGoogle Scholar
  31. 31.
    Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102–106.CrossRefPubMedGoogle Scholar
  32. 32.
    Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM: Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 2004, 44:794–800.CrossRefPubMedGoogle Scholar
  33. 33.
    Bendtsen L, Mattsson P, Zwart JA, Lipton RB: Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003, 23:487–490.CrossRefPubMedGoogle Scholar
  34. 34.
    Loder E, Goldstein R, Biondi D: Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005, 25:124–131.CrossRefPubMedGoogle Scholar
  35. 35.
    Schwedt TJ, Hentz JG, Dodick DW: Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. Cephalalgia 2007, 27:528–534.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.The Neurologic Group of Bucks/Montgomery CountyDoylestownUSA

Personalised recommendations